ASSESSMENT OF THE TREATMENT COMPLIANCE OF CHRONIC HEPATITIS B PATIENTS AT DUC GIANG GENERAL HOSPITAL

THi Hoai Thuong Nguyen, Thuy Linh Luu, Manh Truong Nguyen

Main Article Content

Abstract

Strict adherence to medication is paramount for successful treatment of chronic hepatitis B (CHB). The
purpose of this study was to evaluate the treatment adherence of CHB patients during treatment.
Subjects and methods: A cross-sectional descriptive study with analysis of 73 patients aged 22 to 74 years
with CHB diagnosis being treated with the antiviral medication Tenofovir 300mg at the Hepatitis clinic, Duc
Giang General Hospital (August 2021 - December 12, 2021).
Results and conclusions: In 73 study subjects, the mean age was 56 years old, men accounted for 60.3%.
There were 49 patients with good adherence to treatment, accounting for 67.1% while 24 patients had poor compliance, accounting for 32.9%. Adherent patients had better disease knowledge, good physician relationship, and fewer barriers than poor compliance patients. The proportion of patients who do not use adherence support measures but only rely on habits accounts for 52%, the most commonly used means of compliance support is the telephone ringing (38.3%). The rate of poor adherence in the group with treatment duration ≤ 5 years was 4.3 times higher than the group > 5 years

Article Details

References

1. Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international. 2016. 10:1-98.
2. Nguyen VTT, Law MG, Dore GJ. An enormous hepatitis B virus‐related liver disease burden projected in Vietnam by 2025. Liver International. 2008. 28(4):525-531.
3. Ford N, Scourse R, Lemoine M, et al. Adherence to nucleos (t) ide analogue therapies for chronic hepatitis B infection: a systematic review and meta‐analysis. Hepatology communications. 2018. 2(10):1160-1167.
4. Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis B patients in a routine clinical practice.
Journal of clinical gastroenterology. 2016. 50(2):169-174.
5. Su TH, Hu TH, Chen CY, et al. Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International. 2016. 36(12):1755-1764.
6. Bộ Y tế (2019). Hướng dẫn chẩn đoán và điều trị bệnh viêm gan virus B. Ban hành kèm theo Quyết định số 3310/QĐ-BYT ngày 29 tháng 7 năm 2019 của Bộ trưởng Bộ Y tế.
7. Abreu RM, da Silva Ferreira C, Ferreira AS, et al. Assessment of adherence to prescribed therapy in patients with chronic hepatitis B. Infectious Diseases and Therapy. 2016. 5:53-64.
8. Nguyễn Thúy Mai, Nguyễn Nguyên Huyền, Nguyễn Tuấn Thành. Đánh giá sự tuân thủ điều trị của các bệnh nhân viêm gan virus B mạn tính tại Khoa Khám bệnh, Bệnh viện Bệnh Nhiệt đới Trung ương. Tạp chí Truyền nhiễm Việt Nam. 2017. 1(17):12-17.
9. Peng J, Yin J, Cai S, Yu T, Zhong C. Factors associated with adherence to nucleos (t) ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study. Patient preference and adherence. 2015.41-45.